Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

RPI-78 More Effective Than Morphine

By R&D Editors | June 9, 2009

Nutra Pharma Corp., a biotechnology company that is developing treatments for adrenomyeloneuropathy (AMN), HIV and multiple sclerosis (MS), announced that its wholly-owned drug discovery subsidiary, ReceptoPharm, has published the results of its recent pain study in Toxicon, the official journal of the International Society on Toxinology. The study, which examined ReceptoPharm’s leading drug candidate for the treatment of pain, RPI-78, showed that the pain reducing effects of RPI-78 lasted four-times as long as morphine and without the negative side effects associated with opioid-based pain relievers.

“The results from this study provide a significant step forward in the development of an effective and non-narcotic treatment for moderate to severe pain,” commented Dr. Paul Reid, CEO of ReceptoPharm. “With these results in hand, we believe that RPI-78 could become the first non opioid-based analgesic dedicated to treating Stage II and Stage III pain,” he added.

In the central nervous system, the thalamic parafascicular nucleus (Pf) is considered one of the important processing centers for pain. The ReceptoPharm study showed that RPI-78 had a dose-dependent inhibitory effect on the electrical activity of Pf neurons in male Wistar rats that persisted for at least 2 hours in comparison to the inhibitory effect of morphine, which persisted no longer than 30 minutes. On a molecular basis, RPI-78 was observed to be 4,000 times more potent than morphine. Additionally, the study observed increased serotonin levels in subjects treated with RPI-78, which may explain the improved attitude in those subjects.

“While many opioid-based drugs provide fast and temporary pain relief, the negative side effect profiles and addictive properties of these medicines make them extremely difficult to administer,” explained Rik J. Deitsch, Chairman and CEO of Nutra Pharma. “Because RPI-78 is more effective than morphine and does not produce these negative side effects, we believe that this drug could become the therapy of choice among hospitals and physicians in the near future,” he concluded.

Date: June 8, 2009
Source: Nutra Pharma Corp. 

Related Articles Read More >

IBM’s second-generation, 156-qubit Quantum Heron processors offer reduced error rates, 16× better performance, and 25× faster speeds than 2022 systems. The Heron can run quantum circuits with up to 5,000 two-qubit gate operations using Qiskit—nearly double what IBM achieved in 2023.
Quantum computing edges closer to biotech reality in Moderna-IBM pact
New nanopore sensor paves the way for fast, accurate, low-cost DNA sequencing
E. coli makes Tylenol from plastic waste
2025 R&D layoffs tracker hits 132,075 as Amazon CEO signals AI will cut more jobs
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE